當(dāng)前位置：   首頁 > 需求大廳

標(biāo)題：求購藥品批件 需求名稱：中藥、化藥都可，批文。生產(chǎn)線。 和我聯(lián)系,QQ；1270517234   [更多]

需求藥物研發(fā)中心質(zhì)量管理體系文件，至少包含目錄及管理制度(數(shù)據(jù)，記錄，儀器，物料，計算機(jī)等)   [更多]

各位智友：本人因檢測需要，求分享歐洲藥典10.0檢測 General Chapters部分。應(yīng)包括以下內(nèi)容 2.2.32. Loss on drying 2.4.16. Total ash 2.8.1 Ash insoluble in hydrochloric acid 2.8.2 FOREIGN MATTER 2.2.13 WATER 2.8.4 SWELLING INDEX 2.8.15 BITTERNESS VALUE Appendix XI B1. Ethanol-soluble Extractive Appendix XI B2. Water-soluble Extractive   [更多]

本人由于研發(fā)需要，現(xiàn)想求購全套中藥材生產(chǎn)基地信息，如果可以提供全套信息，價格面議，如果可以提供具體品種的中國種植基地信息，通過驗證齊全且真實(shí)的，每個品種可以獲得500元信息服務(wù)獎勵   [更多]

1、P. A. Prajapati and M. M. Patel, “Formulation and in vitro evaluation of atropine sulphate viscous ocular solutions for the mydriatic and cycloplegic effect,”?International Journal of Pharmaceutical and Applied Sciences, vol. 1, no. 2, pp. 70–78, 2010.?View at Google Scholar 2、D. S. Satya, K. P. Suria, and P. P. Muthu, “Advanced approaches and evaluation of ocular drug delivery system,”?American Journal of PharmTech Research, vol. 1, no. 4, pp. 72–92, 2011.?View at Google Scholar 3、B. K. Nanjwade, D. B. Sonaje, and F. V. Manvi, “In vitro—in vivo?release of ciprofloxacin from ophthalmic formulations,”?International Journal of Pharmacy and Biotechnology, vol. 1, no. 1, pp. 23–28, 2011.?View at Google Scholar 4、Physicochemical properties and stability of nicorandil By Nagai, Hiroshi; Koizumi, Ikue; Haneda, Masatoshi; Imai, Toshikatsu; Kikuchi, Mineo; Shiba, Motoharu From Iyakuhin Kenkyu (1983), 14(6), 968-79. Language: Japanese, Database: CAPLUS 5、Sobean oil partially hydrogenated 最新德國藥典   [更多]

當(dāng)心血管疾病（心臟病或中風(fēng)）確診后，醫(yī)生會提供治療建議，但病人的決定是至關(guān)重要的。美國心臟協(xié)會（AHA）與 以病人為中心的成果研究所（PCORI）合作，網(wǎng)絡(luò)征集文章。你可以是患者，社區(qū)志愿者，家庭成員或任何人，只要你有這方面的親身經(jīng)驗。根據(jù)你的情況來闡述患者的治療決策是怎樣做出的，例如：對壽命的影響，對生活質(zhì)量的影響，費(fèi)用，或其他？同時關(guān)心過程的完整性，時間，等等。。。 “請于2016年6月9日之前將稿件上傳到：https://www.innocentive.com/ar/workspace/challengeDetail?challenge=9933835“ THE CHALLENGE Treatment of heart disease and stroke often requires patients and their families to make many decisions on how to move forward after a cardiac event. Specifically, AHA and PCORI are interested in learning about the “decisional dilemmas” you face – your insights will help guide future research to improve heart health. Based on the input from you and others in the patient and caregiver community, we will identify important concerns and use the perspectives to target research towards what matters most. Despite multiple available treatment options that your physician may describe, you may not always know which option is right/best for you. Tell us about the most difficult decision that you or your family faced when evaluating treatment options for heart disease or stroke. In addition, we would like to understand more about what you considered most important when making this choice or decision. Please pick your top three choices and tell us why they are important to you and your family: Side effects of the treatment Complexity of treatment plan Difficulty in adhering to a treatment Impact on my quality of life Potential to prolong my life Whether the best option for me is selected based on research of people similar to me (personal characteristics such as my age, race and gender) Whether my family history and genetic makeup would influence the effectiveness of a given option Whether a trusted source recommended a specific option The financial impact of the options for me and my family Other:________ Any submission should address the following Submission Requirements: The submission can be from anyone (patient, caregiver, family member, or other)   [更多]

Good Clinical Practice: A Question & Answer Reference Guide 2018 (Electronic)，電子版，要2018年版   [更多]

求購海王藥業(yè)?；撬犷w粒（泰瑞寧）微生物檢測方法   [更多]

技術(shù)要求：我公司為精細(xì)化學(xué)品專業(yè)生產(chǎn)廠家，現(xiàn)閑置一整套手續(xù)齊全流水線車間，配備有先進(jìn)的生產(chǎn)設(shè)備和生產(chǎn)技術(shù)工人，現(xiàn)公司面向社會尋求技術(shù)合作。本公司熱忱歡迎社會各界朋友來廠洽談合作。   [更多]

1、要求提供的信息真實(shí)可靠。 2、要求直接提供賣家信息，不接受中介。 3、藥智技術(shù)轉(zhuǎn)讓數(shù)據(jù)庫里面沒有的信息。   [更多]